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A carbapenem-resistant Acinetobacter pittii strain carrying an OXA-24-like enzyme was isolated in northern Spain in 2008. Se-
quence analysis confirmed the presence of the novel blaOXA-207 gene flanked by the site-specific XerC/XerD-like recombination
binding sites and showing a unique Gly222Val substitution compared to OXA-24. Cloning and kinetic analysis showed that
OXA-207 presents a reduction in the catalytic efficiency against carbapenems and a noticeable increase for oxacillin.
Acinetobacter pittii is a member of the Acinetobacter calcoaceti-cus-Acinetobacter baumannii complex. This species is ecolog-
ically diverse and can produce serious infections and even hospital
outbreaks (1–3). Although this microorganism remains suscepti-
ble to many antimicrobial agents used in clinical practice (4), car-
bapenem-resistant A. pittii isolates carrying oxacillinase genes
have been reported (5, 6). Oxacillinases are chromosomal or plas-
mid-encoded class D -lactamases with heterogeneous structural
and biochemical properties (7), and of these -lactamases, the
carbapenem-hydrolyzing class D -lactamases (CHDLs) are
mainly found in A. baumannii (8). Eventually, acquired CHDLs
can also be found in other non-A. baumannii species, compromis-
ing the therapeutic options for patients infected by these patho-
gens (9, 10). The aim of this study was to characterize a novel
OXA-24 variant in a carbapenem-resistant A. pittii isolate from
Spain.
In April 2008, a carbapenem-resistant Gram-negative cocco-
bacillus was recovered from a bronchial aspirate of a patient ad-
mitted to the Medical Intensive Care Unit in the Hospital Univer-
sitario Marqués de Valdecilla (HUMV), Santander, Spain. The
isolate (HUMV-1588) was initially identified by the automated
system MicroScan Walk-Away (Siemens Healthcare Diagnostic
Inc., West Sacramento, CA) as Acinetobacter baumannii/Acineto-
bacter haemolyticus. Definitive identification of HUMV-1588 as
A. pittii was confirmed by amplified ribosomal DNA restriction
analysis (ARDRA) and sequencing of partial regions of RNA poly-
merase  subunit (rpoB) gene (GenBank accession number
JQ838184), as previously published (11–13). The MICs of differ-
ent antimicrobial agents were determined by using Etest strips
(bioMérieux, Marcy l’Étoile, France) according to the manufac-
turer’s recommendations, and results were interpreted according
to the Clinical and Laboratory Standards Institute (CLSI) (14).
The A. pittii HUMV-1588 strain was resistant to imipenem and
meropenem (MIC of 32 g/ml for both) and intermediate to
cefepime (MIC of 16 g/ml) but maintained susceptibility to cef-
tazidime and cefotaxime (MICs ranging from 2 to 4 g/ml), as
shown in Table 1. High MICs (MICs of 256 g/ml) were ob-
served for the aminopenicillins, isoxazolilpenicillins, ureidopeni-
cillins, and aztreonam. The most active antimicrobial agents
tested were tobramycin and trimethoprim-sulfamethoxazole
(MIC of 0.06g/ml for both). Excellent results were also obtained
for tigecycline and colistin (MICs of 0.125 and 0.25g/ml, respec-
tively), the few options to treat infections caused by multidrug-
resistant Acinetobacter species isolates. Of the tetracyclines, mino-
cycline (MIC, 0.125 g/ml) was more active than doxycycline
(MIC, 0.25 g/ml) and tetracycline (MIC, 2 g/ml). Interesting,
the HUMV-1588 strain was resistant to ciprofloxacin (MIC, 16
g/ml) but maintained susceptibility to levofloxacin (MIC, 2
g/ml).
Genomic DNA from A. pittii HUMV-1588 was extracted, and
multiplex PCR assays were performed to investigate the presence
of CHDLs and metallo--lactamase (MLs) encoding genes, as
previously reported (15–17). The PCR results showed that the
HUMV-1588 strain carried a blaOXA-24-like gene. Based on that,
primers Pre-OXA-24.A (5=AYTTCGBATAAYSSCCATTATGTT
AAATTAAAAGA3=) and Pre-OXA-24.B (5=ATTTCGYATAASG
YGTATTATGTTAATTTTAGAAA3=), amplifying the entire
blaOXA-24-like genes and surrounding regions, including its flank-
ing region composed of XerC/XerD-like recombination sites,
were designed according to previously reported sequences (18,
19). PCR conditions were as follows: (i) 95°C for 5 min; (ii) 35
cycles, with 1 cycle consisting of 95°C for 30 s, 45°C for 30 s, and
72°C for 2 min; (iii) 72°C for 7 min. PCR products were analyzed
on a 1% (wt/vol) agarose gel stained with ethidium bromide. PCR
products were purified by using a High Pure PCR product purifi-
cation kit (Roche Diagnostics, Mannheim, Germany), and bidi-
rectional DNA sequencing was performed by Macrogen Inc.
(Seoul, South Korea). Sequencing of a 967-bp amplicon showed
the presence of an open reading frame of 828 bp which encoded a
product predicted to have 99.0% amino acid identity with OXA-
24. This blaOXA-24-like gene presented a G¡T mutation at nucle-
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otide 665, causing a unique Gly222Val change, and the -lacta-
mase was designated OXA-207 (GenBank accession number
JQ838185). In addition, the blaOXA-207 gene was flanked by the
site-specific recombination XerC-XerD-like binding sites. Al-
though the XerC/XerD-mediated recombination mechanism is
not well understood, it seems that XerC/XerD recombination sites
are key structures associated with the spreading of blaOXA-24-like
genes (19, 20). Overall, it is clear that the OXA-24 variants are able
to cause resistance to carbapenems by themselves, since their ex-
pression is not influenced by the presence of additional promoters
brought by insertion sequences, as happens with the majority of
CHDLs (7, 8, 20).
A comparison of amino acid sequences of the seven OXA-24
variants known at this time, and the closely related OXA-143 and
OXA-182 enzymes included in the OXA-143 group, is shown in
Fig. 1. The three conserved motifs (STKF, FGN, and KSG) respon-
sible for the formation of the active site are identical among the
three CHDL groups. The unique Gly222Val substitution present
in OXA-207 is near the third conserved motif KSG and adjacent to
Met-223, which has been defined as a very important residue from
a structural point of view for the biochemical properties of the
active site of the OXA-24 enzyme, also called OXA-40 (21, 22). A
previous analysis of the crystal structure of OXA-24 showed that
the specificity for carbapenems is determined by a hydrophobic
barrier that is associated with the amino acid residues Tyr-112 and
Met-223 (21, 22) that define a tunnel across the active site of
OXA-24 and orientate the access of carbapenem to the catalytic
binding site (21). The small size of the carbapenems and the hy-
drophobic feature of the tunnel-like channel are appropriate to
accommodate these drugs rather than the oxacillin (22).
In order to compare the kinetic features of OXA-24 and OXA-
207, the blaOXA-24 and blaOXA-207 genes were amplified in parallel
by PCR with the primers OXA24/207-Fow-XbaI (Fow stands for
forward) (5=-CCCTCTAGAATGAAAAAATTTATACTTCC-3=)
and OXA24/207-Rev-NcoI (Rev stands for reverse) (5=-CCCCCA
TGGTTAAATGATTCCAAGATTTTC-3=). The purified ampli-
cons were cloned between XbaI and NcoI restriction sites in
pET-RA plasmid harboring a rifampin resistance gene (GenBank
accession number HM219006). The constructions were used to
transform Acinetobacter baylyi ADP1 cells by electroporation (25
F, 200 , 2.5 kV), with a Gene Pulser II (Bio-Rad, Richmond,
CA). Transformants were selected on LB plates supplemented
with 50 g/ml of ampicillin and 50 g/ml of rifampin, and the
presence of CHDL genes was confirmed by sequencing. The MICs
of ampicillin (Sigma, St. Louis, MO, USA), imipenem (Merck,
Whitehouse Station, NJ), and meropenem (AstraZeneca, London,
United Kingdom) were determined by the broth microdilution
method (23) for the A. pittii HUMV-1588 and A. baylyi ADP1
strains, as well as for the A. baylyi ADP1 transformants. Other
antibiotics were determined by Etest strips. Data are presented in
Table 1. The MICs of ampicillin, imipenem, and meropenem for
A. baylyi ADP1 expressing the blaOXA-207 gene increased to values
similar to those obtained by A. baylyi ADP1 expressing the
blaOXA-24 gene and A. pittii HUMV-1588. To purify OXA-207, the
corresponding gene was cloned into the pGEX-6P-1 vector with
BamHI and EcoRI restriction sites to produce translational fu-
sions with the glutathione S-transferase (GST) gene. The primers
used for amplification of the gene lacking the signal peptide are
OXA24/207-pepBamHI (5=-AAGGATCCTCTATTAAAACTAA
ATCTGAAG-3=) and OXA24/207-RevEcoRI (5=-AAAGAATTCT
TAAATGATTCCAAGATTTTC-3=). The OXA-207 enzyme was
purified to homogeneity with the GST gene fusion system (Amer-
sham Pharmacia Biotech, Europe GmbH) in accordance with the
manufacturer’s instructions and with other publications (21). The
mature purified protein, lacking the GST fusion protein, appeared
on SDS-polyacrylamide gels as a band of 29.1 kDa (95% purity).
The concentrations of the purified proteins were determined by a
protein assay (Bio-Rad, Richmond, CA). The additional nonnat-
ural residues added to the mature protein were Gly-Pro-Leu-Gly-
Ser. As the procedure to purify -lactamase enzymes is always the
same, the OXA-24 protein used as a comparator in our work,
harbored the same identical five amino acids. The protein OXA-
207 was subjected to further biochemical studies with ampicillin,
oxacillin, imipenem, and meropenem. The antibiotic molar ex-
tinction coefficients in the spectrophotometric assays and the
wavelengths used for measurements for ampicillin, oxacillin, imi-
penem, and meropenem were the same as previously published
(21).
TABLE 1 Antimicrobial susceptibility profiles of A. pittii and A. baylyi determined by broth microdilution
Antimicrobial agent(s)
MIC (g/ml) of antimicrobial agent(s) ina:
A. pittii
(blaOXA-207)
A. baylyi
ADP1(pET-RAblaOXA-24)
A. baylyi
ADP1(pET-RAblaOXA-207)
A. baylyi
ADP1(pET-RA)
Ampicillin 4,096 1,024 512 4
Ampicillin-sulbactamb 16/8 16/8 16/8 2/1
Piperacillin 512 256 256 8
Piperacillin-tazobactamc 256/8 256/8 256/8 16/8
Cefoxitin 256 24 24 24
Ceftazidime 2 2 2 2
Cefotaxime 4 4 4 4
Cefepime 16 4 4 1
Aztreonam 256 4 8 2
Imipenem 32 32 16 0.125
Meropenem 32 32 16 0.125
a Antimicrobial susceptibility profiles of the OXA-207-producing A. pittii strain, the host strain A. baylyi ADP1 with the plasmid pET-RA alone, and A. baylyi ADP1 transformants
harboring the plasmid pET-RA with the blaOXA-24 or blaOXA-207 gene. The MICs of the antimicrobial agents used in combinations are shown in the same order as the drugs (e.g.,
the MIC of ampicillin or piperacillin is shown before the slash).
b Ampicillin-sulbactam was used at a 2:1 ratio.
c Tazobactam was used at a fixed concentration of 8 g/ml.
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Biochemical studies (kcat and Km) were carried out in triplicate
in phosphate-buffered saline (PBS) buffer with bovine serum al-
bumin (BSA) (20g/ml) at 25°C in a Nicolet Evolution 300 spec-
trophotometer (Thermo Electron Corporation, Waltham, MA,
USA) and quartz cuvettes with an optical path length of 0.2 cm.
The data were analyzed with Vision Pro software (Thermo Elec-
tron Corporation). The kinetic parameters for nitrocefin were de-
termined from the initial rates by Hanes-Woolf linearization of
the Henri-Michaelis-Menten equation. The Km values for ampi-
cillin, oxacillin, imipenem, and meropenem were calculated as Ki
values in competitive assays with nitrocefin (Oxoid, Basingstoke,
Hants, United Kingdom) as the substrate. TheVmax was calculated
by considering an antibiotic concentration 10 times the Km, and
the kcat values were obtained under zero-order conditions (sub-
strate concentration  Km). The catalytic efficiencies for ampi-
cillin observed in the OXA-24 and OXA-207 enzymes are similar,
but there was an increase in the Km for OXA-207. Although both
enzymes showed high affinities for imipenem and meropenem,
OXA-24 efficiently hydrolyzed meropenem and imipenem,
hydrolyzing meropenem and imipenem 7 and 2.5 times better
than OXA-207 (Table 2), respectively. However, the OXA-207
enzyme (kcat/Km 8,934) shows high rates of hydrolysis for oxa-
cillin compared to the OXA-24 enzyme (kcat/Km 202).
Santillana et al. (21) determined the crystal structure of
OXA-24 at a resolution of 2.5 Å and then resolved the biochemical
mechanism toward carbapenems of this enzyme. The structure
shows that carbapenem’s substrate specificity is determined by a
hydrophobic barrier that is established through the specific ar-
rangement of the Tyr-112 and Met-223 side chains, which define a
tunnel-like entrance to the active site. The importance of these
FIG 1 Comparison of the amino acid sequences of the seven OXA-24 variants (OXA-24, OXA-25, OXA-26, OXA-72, OXA-139, OXA-160, and OXA-207) with
the related CHDL groups (OXA-143 and OXA-182), using the ClustalW multiple-sequence alignment program. All sequences were obtained with the accession
numbers provided by the-Lactamase Classification and Amino Acid Sequences website (http://www.lahey.org/Studies/). The amino acid sequences of OXA-24
and OXA-40 are identical (25, 26). Conserved motifs are boxed. Conserved amino acids are indicated by periods. The Gly222Val substitution in the predicted
amino acid sequence of OXA-207 is indicated by a black arrow.
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residues was further confirmed by mutagenesis studies. In previ-
ous biochemical studies performed with OXA-24 (21) when Met-
223 was replaced with Ala in OXA-24 either alone or in combina-
tion with the replacement Tyr112Ala (double mutant), a
reduction in the catalytic efficiency against carbapenems was ob-
served (21). However, analysis of each independent residue
showed that Tyr-112 is more important than Met-223 ing confer-
ring high MICs for imipenem and meropenem in the bacterial
strain expressing OXA-24. It seems that the Tyr-112 residue is
essential for catalytic efficiency against carbapenems, because it
hooks the 6--hydroxyethyl group of these -lactam antibiotics
before catalysis and introduces the antibiotic molecule onto the
active site.
With respect to oxacillin, the activity of OXA-24 toward this
antibiotic (kcat/Km  200) was very low with other oxacillinases
(21). This may be due to the bulky methylphenylisoxazolyl moiety
of the oxacillin molecule located at the left position of the -lac-
tam ring. Therefore, access of this substrate to the active site in the
wild-type (WT) OXA-24 enzyme may be difficult, because of
steric restrictions and the architecture of the catalytic binding site.
It is interesting that the Gly222Val substitution observed in
OXA-207 occurs at the amino acid position preceding Met-223,
whose role in substrate binding and catalysis was previously stud-
ied by mutagenesis as discussed above (21). Although the
Gly222Val substitution observed in our study may alter the tun-
nel-like entrance used for the carbapenems in the active center of
OXA-207, this change seems to be insufficient to abrogate the
entrance of these antibiotics into the active site of the enzyme, as
Tyr-112 is present in OXA-207 and may still help orientate car-
bapenem molecules to the active site of OXA-207 but with less
efficiency than the wild-type OXA-24 enzyme. However, this
change seems sufficient to abrogate any steric restriction for oxa-
cillin, thus facilitating the entrance of this antibiotic to the OXA-
207 active center, with kcat/Km ratios (mM
	1 s	1) for oxacillin and
OXA-24 and OXA-207 of 202 and 8,907, respectively.
OXA-24 is the most disseminated CHDL in A. baumannii clin-
ical isolates in Spain (18, 24), and this is the first report of an
OXA-24 variant in a non-A. baumannii species in Spain. Although
OXA-207 more weakly hydrolyzed meropenem than imipenem
compared to OXA-24, this CHDL significantly contributes to the
resistance to both carbapenems in the A. pittii HUMV-1588
strain. In addition, the presence of the same XerC/XerD structure
flanking the novel OXA-207 found in A. pittii HUMV-1588, as
well as in the OXA-24-producing A. baumannii clones identified
in our hospital during the last 5 years (unpublished data), indicate
a possible gene transfer from A. baumannii to A. pittii.
In conclusion, we have identified a carbapenem-resistant A.
pittii clinical isolate harboring the novel OXA-207 enzyme in
Spain. Our findings suggest that the unique mutation present in
the OXA-207 enzyme changed its catalytic activity against carbap-
enems and oxacillin. The emergence of this CHDL in A. pittii is a
concern, as it would drastically compromise the use of -lactams
to treat infections caused by this pathogen.
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